NASDAQ:SGMT Sagimet Biosciences (SGMT) Stock Price, News & Analysis $7.58 -0.40 (-4.95%) As of 11:18 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sagimet Biosciences Stock (NASDAQ:SGMT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sagimet Biosciences alerts:Sign Up Key Stats Today's Range$7.61▼$8.0050-Day Range$7.98▼$11.1752-Week Range$4.50▼$11.45Volume472,720 shsAverage Volume1.20 million shsMarket Capitalization$471.48 millionP/E RatioN/ADividend YieldN/APrice Target$26.63Consensus RatingModerate Buy Company Overview Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that target fatty acid synthase (FASN), an enzyme involved in the production of fatty acids. The company’s research is aimed at treating diseases associated with abnormal lipid metabolism and excess fat production. Sagimet’s lead investigational product is denifanstat, an oral, selective FASN inhibitor formerly known as TVB-2640. The company is evaluating denifanstat primarily for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that can involve inflammation, fat accumulation and fibrosis. Sagimet has also investigated the compound in other conditions, including acne and certain cancers, through earlier-stage clinical programs and research collaborations. The company was previously known as 3-V Biosciences and is based in San Mateo, California. Sagimet’s operations are centered on drug discovery, clinical development and regulatory advancement of its FASN inhibitor programs, with clinical activities conducted through research and medical networks in the United States and other regions. The company’s common stock trades on the Nasdaq under the symbol SGMT.AI Generated. May Contain Errors. Read More Sagimet Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreSGMT MarketRank™: 3.29536476165 of 5 starsSagimet Biosciences scored higher than 66% of companies evaluated by MarketBeat, and ranked 361st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingSagimet Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialSagimet Biosciences has a consensus price target of $26.63, representing about 243.2% upside from its current price of $7.76.Amount of Analyst CoverageSagimet Biosciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sagimet Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sagimet Biosciences are expected to grow in the coming year, from ($1.14) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sagimet Biosciences is -6.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sagimet Biosciences is -6.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSagimet Biosciences has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sagimet Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.34% of the float of Sagimet Biosciences has been sold short.Short Interest Ratio / Days to CoverSagimet Biosciences has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Sagimet Biosciences has recently increased by 9.03%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSagimet Biosciences does not currently pay a dividend.Dividend GrowthSagimet Biosciences does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.86 News SentimentSagimet Biosciences has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Sagimet Biosciences this week, compared to 4 articles on an average week.Search Interest17 people have searched for SGMT on MarketBeat in the last 30 days. This is an increase of 183% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Sagimet Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sagimet Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $920,491.00 in company stock.Percentage Held by Insiders11.50% of the stock of Sagimet Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.86% of the stock of Sagimet Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sagimet Biosciences' insider trading history. Receive SGMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sagimet Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SGMT Stock News HeadlinesSagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China TrialOctober 9, 2026 | finance.yahoo.comSagimet Reports Sustained Acne Improvements With Denifanstat Through 52 WeeksOctober 9, 2026 | rttnews.comAI Microcap Teams With Gentex on Next-Gen Military HelmetsMorgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion robots operating worldwide. But even the most advanced machines still lack one human sense: smell. One microcap is developing an AI-powered sensor, smaller than a deck of cards, now in hands-on integration with Gentex, whose helmet systems serve U.S. forces and more than 20 NATO nations.October 14 at 1:00 AM | Capital Trends (Ad)Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the ...October 9, 2026 | finance.yahoo.comSagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology ConferenceOctober 9, 2026 | globenewswire.comHC Wainwright Has Optimistic Opinion of SGMT FY2026 EarningsOctober 7, 2026 | americanbankingnews.comHC Wainwright Has Strong Forecast for SGMT FY2029 EarningsOctober 6, 2026 | americanbankingnews.comSagimet Biosciences (NASDAQ:SGMT) Shares Down 6% - What's Next?October 5, 2026 | americanbankingnews.comSee More Headlines SGMT Stock Analysis - Frequently Asked Questions How have SGMT shares performed this year? Sagimet Biosciences' stock was trading at $5.92 on January 1st, 2026. Since then, SGMT shares have increased by 31.1% and is now trading at $7.76. How were Sagimet Biosciences' earnings last quarter? Sagimet Biosciences Inc. (NASDAQ:SGMT) released its earnings results on Tuesday, August, 11th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.01. When did Sagimet Biosciences IPO? Sagimet Biosciences (SGMT) raised $85 million in an initial public offering on Friday, July 14th 2023. The company issued 5,312,500 shares at a price of $15.00-$17.00 per share. How do I buy shares of Sagimet Biosciences? Shares of SGMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sagimet Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sagimet Biosciences investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Iovance Biotherapeutics (IOVA), Energy Transfer (ET) and Tesla (TSLA). Company Calendar Last Earnings8/11/2026Today10/14/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SGMT's financial health is in the Green zone, according to TradeSmith. SGMT has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SGMT CIK1400118 Websagimet.com Phone650-561-8600FaxN/AEmployees16Year Founded2006Price Target and Rating Average Price Target for Sagimet Biosciences$26.63 High Price Target$56.00 Low Price Target$7.00 Potential Upside/Downside+248.9%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.96% Return on Assets-30.57% Debt Debt-to-Equity RatioN/A Current Ratio45.03 Quick Ratio45.02 Sales & Book Value Annual Sales$2 million Price / Sales237.26 Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book2.23Miscellaneous Outstanding Shares62,160,000Free Float55,011,000Market Cap$474.53 million OptionableOptionable Beta3.46 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:SGMT) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
